$100M market cap. $240M in cash. Somebody filed a 13D.

The math is not complicated. Seer, Inc. trades at 42 cents on the dollar of its own cash pile. The operating business — a proteomics platform with 82 instruments installed across 20 countries — is valued by the market at negative $140 million. Either the market thinks management will incinerate $240M with nothing to show for it, or the market is wrong. On December 9, 2025, an activist showed up to find out which.

The Setup

Seer makes the Proteograph Product Suite — nanoparticle-based sample prep for mass spectrometry proteomics. The pitch: unbiased deep proteomics at population scale, 9,000+ proteins per sample, 1,000+ samples per week. A Nature Genetics paper (November 2025) showed up to 1/3 of results from competing affinity platforms (Olink, SomaScan) are false positives from epitope effects. The science is real.

The commercial execution is not.

Revenue: $15.5M (2022) → $16.7M (2023) → $14.2M (2024) → $16.6M (2025). Four years. Flat. The installed base grew 67% in 2025 alone — from 49 to 82 instruments — and revenue barely moved. They grew consumable kit volume 69%. Revenue grew 17%. The gap tells you everything: they're giving away the razors (60% of 2025 placements were free via their SIPP program) and discounting the blades.

They don't have a Chief Commercial Officer. They're hiring one now. In year five. Eighty-two instruments in four years with no head of sales is not a go-to-market strategy — it's a science experiment that accidentally has customers.

Meanwhile the competitive landscape got dramatically worse. Thermo Fisher acquired Olink for $3.1B in July 2024. Olink does $200M+ in revenue, growing mid-teens, with 1,400 publications and TMO's global distribution machine behind it. Illumina acquired SomaLogic in late 2025. The two largest life science tools companies on earth now each own an affinity proteomics platform. Seer is a $16.6M company with 70 publications and a co-marketing agreement that TMO doesn't mention in earnings calls.

The Nature Genetics paper? Contested. An independent Edinburgh preprint (June 2025) puts the false-positive rate at 12%, not 33%. The science is debated. Commercially, Olink grows regardless.

Then the Activist Showed Up

On December 9, 2025, the Radoff-JEC group filed a Schedule 13D disclosing 3,650,000 shares — 6.5% of SEER. They stated they believe the stock is "undervalued" and are engaging management on:

• Strategic review (consider selling the company)
• Board composition changes (force representation)
• Capital allocation changes (stop burning cash on side projects)
• Ownership structure changes

On the exact same day — December 9 — all Class B shares (10x voting rights) were converted to Class A. The founders gave up their voting control. This was not a coincidence. It was a concession.

The board's counter-moves came in February:

• Feb 25: Authorized a new $25M share repurchase (shareholder-friendly gesture)
• Feb 26: Adopted a Tax Benefit Preservation Plan — a 4.9% poison pill that blocks anyone from accumulating above 4.9% ownership

The poison pill protects $262M in NOL carryforwards. It also protects the board from further activist accumulation. The Radoff-JEC group is grandfathered at 6.5% but can't buy another share.

Here's the pressure point: the poison pill expires in February 2027 if shareholders don't ratify it. Vanguard and BlackRock — both significant holders — routinely vote against poison pills on governance grounds. If the pill fails ratification, the activist can accumulate freely. The clock is ticking.

The Math That Won't Go Away

At $1.78 per share with 56.2M shares outstanding:

Even in the bear case — burn cash for five years, shut down, return nothing — the NPV of the remaining cash is $3.20/share. That's 80% above the current price.

Management claims current cash is "sufficient to reach cash flow breakeven." They cut opex 19% YoY ($107M → $86M) without mass layoffs. SBC fell 45%. The burn is declining. These are not the actions of a company planning to immolate its balance sheet.

The $25M buyback at current prices retires ≈14M shares (25% of float at $1.78). Combined with $22M already repurchased, the board has spent $47M buying its own stock — nearly half the market cap. They are telling you something.

What the Activist Changes

Before the 13D, SEER was a value trap. Good math, no catalyst. The $140M discount to cash could persist indefinitely because nobody had the leverage to force the unlock.

Now someone does.

The activist playbook at below-cash companies is well-established: demand strategic review → force board seats → push for capital return or sale. The timeline compresses around the poison pill ratification vote. If shareholders reject it (I put this at 55% probability), the activist's leverage doubles overnight.

The acquirer logic works too. Bruker flagged "proteomics" as an M&A target area in Q4 2025. SEER's technology, 82-instrument installed base, Thermo Fisher co-marketing relationship, and $262M in NOLs are worth something to a strategic buyer — even if the standalone commercial trajectory is weak. At $100M market cap with $240M in cash, an acquirer effectively gets paid to buy the technology.

The Bear Case Is Real

Don't mistake this for a table-pounding buy.

Four years of flat revenue is empirical, not theoretical. The competitive landscape is brutal and getting worse. Academic customers (40-60% of the base) face NIH funding uncertainty. No insider is buying stock with their own money despite the below-cash discount. The options market doesn't exist — too illiquid to hedge. And management just invested another $1.5M into PrognomiQ, their pre-revenue diagnostics spinoff that has already destroyed $10M in carrying value.

The revenue inflection everyone keeps waiting for requires proteomics consumable economics we can't independently verify. Management guided +3% for 2026. They don't expect it either.

Three Paths

The expected value is meaningfully positive. The base case — activist forces some form of value realization without revenue inflection — gets you to $3. The bear case is a managed decline to $1.20 (floor from remaining cash).

The key variable is no longer "will proteomics consumables inflect?" It's "will the activist succeed against the board?" That's a governance question with analyzable inputs: shareholder composition, proxy rules, poison pill ratification, institutional voting patterns. We can assess this. We can't assess proteomics lab purchasing cycles.

What to Watch

1. 13D amendments from Radoff-JEC — any escalation, proxy materials, additional buyers
2. Poison pill ratification — annual meeting proxy, ISS/Glass Lewis recommendations
3. Q1 2026 earnings (May 12) — revenue >$5M/quarter breaks the "flat four years" narrative
4. CCO hire announcement — a real commercial leader could be the operational catalyst
5. Bruker M&A activity — any proteomics acquisition would reprice SEER's takeout value

Not a position. The Radoff-JEC track record needs research before sizing. But this went from "value trap, no key" to "contested value with a forcing function." That's a different animal.